Two compounds from the endophytic Colletotrichum sp. of Ginkgo biloba

Antagonistic Activity of Endophytic Fungi Isolated from Globba patens Miq. Rhizome against Human Pathogenic Bacteria

The emergence of bacterial infections caused by resistant strains poses a threat to the development of new antibiotics. The majority of antibiotics being produced has been accelerated through the finding of newly reported natural products, especially those originated and produced by biological sources. Endophytic fungi residing in medicinal plants may be regarded as potential sources and encourage the exploration of more plant species for their antimicrobial activity. Our current study reports on the assemblage of endophytic fungi that colonize the rhizomes, using Globba patens a representative of Zingiberaceous species from North Sumatra. Twenty-six fungal morphotypes were obtained and differentiated by their morphological features. Each isolate was tested against human pathogenic bacteria namely Staphylococcus aureus ATCC® 29213™, Methicillin-resistant S. aureus (MRSA) ATCC® 43300™, Escherichia coli ATCC® 25922™, and Enteropathogenic E. coli (EPEC) K11 in a dual culture assay. The results revealed that the majority of fungal isolates were strong antagonists against S. aureus and E. coli but not against MRSA and EPEC. Isolate Gp07 was the most potential fungus with a wide range of antibacterial activities and was subjected to further species-level identification based on its morphological characteristics and DNA sequence in the ITS-rDNA region. The isolate Gp07 was identified as Colletotrichum siamense, yet the presence of C. siamense in the rhizome of G. patens is not fully understood while possibly being characterized as the antibiotics-producing agent in the future.

Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Discovery: Insights, Avenues, and Challenges

Fungal endophytes are well-established sources of biologically active natural compounds with many producing pharmacologically valuable specific plant-derived products. This review details typical plant-derived medicinal compounds of several classes, including alkaloids, coumarins, flavonoids, glycosides, lignans, phenylpropanoids, quinones, saponins, terpenoids, and xanthones that are produced by endophytic fungi. This review covers the studies carried out since the first report of taxol biosynthesis by endophytic Taxomyces andreanae in 1993 up to mid-2020. The article also highlights the prospects of endophyte-dependent biosynthesis of such plant-derived pharmacologically active compounds and the bottlenecks in the commercialization of this novel approach in the area of drug discovery. After recent updates in the field of 'omics' and 'one strain many compounds' (OSMAC) approach, fungal endophytes have emerged as strong unconventional source of such prized products.